Preventive dendritic cell vaccination in healthy Lynch syndrome mutation carriers
Harm Westdorp(Radboud University Nijmegen), I. Jolanda M. de Vries(Radboud University Nijmegen), Gerty Schreibelt(Radboud University Nijmegen), M.J.L. Ligtenberg(Radboud University Nijmegen), Tanya M. Bisseling(Radboud University Nijmegen), Winald R. Gerritsen(Amsterdam UMC Location Vrije Universiteit Amsterdam), Irıs D. Nagtegaal(Radboud University Nijmegen), Carl G. Figdor(Radboud University Nijmegen), Steve Boudewijns(Bravis Ziekenhuis), Anna L. de Goede(Radboud University Nijmegen), Michelle M. van Rossum(Unknown), Mark A.J. Gorris(Salk Institute for Biological Studies)
Cited by 8
Related Papers
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
|Annals of Oncology|2012|1.5k
Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy
|Nature Biotechnology|2005|823
Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline <i>CDH1</i> mutation carriers
|Journal of Medical Genetics|2015|567
Hereditary diffuse gastric cancer: updated clinical practice guidelines
|The Lancet Oncology|2020|493